ライフサイエンスコーパス: ofloxacin

1 ceftazidime, nitrofurantoin, nalidixic acid, ofloxacin.

2 ncrease persisters to ampicillin compared to ofloxacin.

3 m (S), 16 to 24 mm (I), and </=15 mm (R) for ofloxacin.

4 norfloxacin, and 1.17 (95% CI, .59-2.31) for ofloxacin.

5 g amoxicillin, ampicillin, lomefloxacin, and ofloxacin.

6 ipenem and with Klebsiella pneumoniae versus ofloxacin.

7 tibility to ciprofloxacin, sparfloxacin, and ofloxacin.

8 in 1%, gatifloxacin 0.3%, moxifloxacin 0.5%, ofloxacin 0.3%) and used only their assigned antibiotic

9 mug/ml), moxifloxacin (0.06 to 0.5 mug/ml), ofloxacin (0.25 to 2 mug/ml), amikacin (0.25 to 2 mug/ml

10 oxicillin was predominantly prescribed, only ofloxacin (1 ng.L(-1)) and sulfamethoxazole (4 ng.L(-1))

11 ard ratios were 1.49 (95% CI, 1.05-2.09) for ofloxacin, 1.94 (95% CI, 1.32-2.85) for ciprofloxacin pl

12 ifampicin]; rrs 1400 [kanamycin]; gyrA A90V [ofloxacin]; 1995 [95% HPD: 1988-1999]) prior to the outb

13 otaxime, a cell wall synthesis inhibitor, to ofloxacin, a fluoroquinolone inhibitor of DNA gyrase, an

14 ion against ciprofloxacin, levofloxacin, and ofloxacin and by disk diffusion using EUCAST or CLSI met

15 with the clinical isolates was achieved with ofloxacin and chloramphenicol (100%), and the lowest lev

16 oup of antibiotics (moxifloxacin followed by ofloxacin and ciprofloxacin).

17 s resulted in 92% category agreement between ofloxacin and ciprofloxacin.

18 ins did not protect cells from cefotaxime or ofloxacin and had an impaired ability to protect from mi

19 nt tuberculosis strains and quantified their ofloxacin and moxifloxacin MIC by testing growth at six

20 There was 100% concordance between ofloxacin and moxifloxacin susceptibilities.

21 conferred different levels of resistance to ofloxacin and moxifloxacin.

22 n at the lowest concentration (0.003 mg/ml), ofloxacin and norfloxacin inhibited keratocyte prolifera

23 confer resistance to isoniazid, rifampicin, ofloxacin and streptomycin.

24 ate), the fluoroquinolones ciprofloxacin and ofloxacin and vemurafenib.

25 Furthermore, ciprofloxacin, norfloxacin, ofloxacin, and gatifloxacin exhibited concentration-depe

26 at confer resistance to isoniazid, rifampin, ofloxacin, and moxifloxacin occur the most frequently.

27 d no very major errors, one major error with ofloxacin, and numerous minor errors with the quinolones

28 Ciprofloxacin, ofloxacin, and pefloxacin disks detected all isolates re

29 loci for 16 in vitro-derived recombinants of ofloxacin- and rifampin-resistant L(1) and D strains, re

30 generation quinolones, (aOR: 2.7 [1.7-4.3]), ofloxacin (aOR: 2.3 [1.3-3.8]), ethionamide or prothiona

31 ted odds ratio [aOR]: 2.5 [95% CI 1.1-6.0]), ofloxacin (aOR: 2.5 [1.6-3.9]), ethionamide or prothiona

32 Systemic ofloxacin as adjunct to open flap surgery is able to sup

33 resistance to doxycycline, azithromycin, and ofloxacin at concentrations >4.0 microg/mL.

34 eakpoints for Salmonella to levofloxacin and ofloxacin, but breakpoints for assigning disk diffusion

35 levofloxacin and 4 of 4 laboratories testing ofloxacin by an MIC method correctly reported resistant

36 r susceptibility to rifampin, isoniazid, and ofloxacin by using the conventional submerged-disk propo

37 which results in a moderate increase in the ofloxacin, carbenicillin, and tobramycin MICs.

38 , patients were treated with single doses of ofloxacin, cefixime, or ceftriaxone.

39 gh sensitivity, with limits of detection for ofloxacin, chloramphenicol, and streptomycin of 0.3, 0.1

40 Included ear drops were quinolones (ofloxacin, ciprofloxacin plus hydrocortisone, or ciprofl

41 Neither the levofloxacin nor the ofloxacin disk yielded good separation of isolates with

42 on preventive therapy as per local guidance: ofloxacin, ethambutol, and high-dose isoniazid for 6 mon

43 katG (isoniazid), pncA (pyrazinamide), gyrA (ofloxacin/fluoroquinolone), and rrs (aminoglycosides)-we

44 detection of Aa were treated with 2x200 mg/d ofloxacin for 5 days as adjunct to open flap surgery (te

45 hway by which Escherichia coli persisters to ofloxacin form in response to a carbon source transition

46 Even though the high level of resistance to ofloxacin found in Pakistan is worrisome because it migh

47 he cases of levofloxacin, ciprofloxacin, and ofloxacin, inhibition of HERG occurs at concentrations m

48 luoroquinolone antibiotics ciprofloxacin and ofloxacin interact with UVA radiation to generate reacti

49 Ofloxacin is a fluoroquinolone antibiotic that kills non

50 herichia coli, and found that persistence to ofloxacin is inversely correlated with the capacity of n

51 oxacin, the active l-isomer of the quinolone ofloxacin, is now widely accepted for treatment of multi

52 haloperidol, erythromycin, procainamide, and ofloxacin known to activate T2Rs.

53 populations were eradicated at low levels of ofloxacin, leaving a fraction of essentially invulnerabl

54 d, 98.7% for rifampin, 97.6% for quinolones (ofloxacin, levofloxacin, or moxifloxacin), 99.2% for ami

55 Evidence is mounting that ciprofloxacin and ofloxacin may be safely used to treat serious infections

56 regimens consisted mainly of ethambutol and ofloxacin; mean length of therapy 9 months.

57 inst the ciprofloxacin MICs and that the new ofloxacin MIC breakpoints resulted in 92% category agree

58 thambutol, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxacin, ethionamide, para-aminosalicyli

59 eptomycin, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxacin, ethionamide, para-aminosalicyli

60 For ofloxacin, no very major errors were observed, and major

61 us concentrations of gentamicin, tobramycin, ofloxacin, norfloxacin, and ciprofloxacin.

62 The surface complexation behavior of ofloxacin (OFX), a zwitterionic fluoroquinolone antibiot

63 d (INH), rifampin (RIF), moxifloxacin (MOX), ofloxacin (OFX), amikacin (AMK), kanamycin (KAN), and ca

64 norfloxacin (NRFX, IC(50), 0.78 mug L(-1)), ofloxacin (OFX, IC(50), 1.84 mug L(-1)), flumequine (Flu

65 The quinolone-specific aptamers bound to ofloxacin, one of the most frequently prescribed fluoroq

66 Preoperative topical application of ofloxacin or ciprofloxacin results in a satisfactory min

67 , participating women initiated therapy with ofloxacin or levofloxacin.

68 comparator drugs: cefixime, chloramphenicol, ofloxacin, or ceftriaxone.

69 n (p = 0.001), gatifloxacin (p = 0.003), and ofloxacin (p = 0.002) compared to exoU(-) isolates.

70 equired for formation of both ampicillin and ofloxacin persisters, and we demonstrated that higher sy

71 nucleoid-associated proteins were unique for ofloxacin persisters.

72 gain (median of 1 kg), and the finding that ofloxacin plus ursodeoxycholic acid was not superior to

73 Ofloxacin produces two peaks in the ion mobility distrib

74 om 2002 to 2009 were screened for phenotypic ofloxacin resistance (>2 mug/ml).

75 ce method for detection of ciprofloxacin and ofloxacin resistance in 195 clinical isolates of the fam

76 High levels of ofloxacin resistance were detected in Pakistan.

77 As expected, gyrA (confers ofloxacin resistance) and rpoB (confers rifampin resista

78 t cells were simultaneously infected with an ofloxacin-resistant (Ofx(r)) mutant of a serovar L1 stra

79 Of 25 ofloxacin-resistant isolates, 11 (44%) did not have prev

80 fected in the absence of antibiotics with an ofloxacin-resistant mutant and a second mutant that was

81 on of resistance to rifampin, isoniazid, and ofloxacin, respectively.

82 We also did this for isoniazid, kanamycin, ofloxacin, rifampicin, and streptomycin resistance in My

83 river, only persistent antibiotic compounds (ofloxacin, sulfamethoxazole) were found, but they did no

84 For each resistant isolate, two ofloxacin-susceptible isolates were selected: one with a

85 May 2010 through April 2011 if exposed to an ofloxacin-susceptible, MDR tuberculosis source case.

86 ed antibiotics (sulfamethazine, norfloxacin, ofloxacin, tetracycline, and erythromycin) have been det

87 e MIC zone scattergrams for levofloxacin and ofloxacin, the following disk diffusion breakpoints gene

88 f the present study was to evaluate systemic ofloxacin therapy as adjunct to flap surgery.

89 and 12 months following adjunctive systemic ofloxacin therapy, Aa was suppressed below detectable le

90 s on cerulenin, chlorpromazine, ethionamide, ofloxacin, thiolactomycin and triclosan.

91 ions of resistance ranged from 1.0-16.6% for ofloxacin, to 0.5-12.4% for levofloxacin, and 0.9-14.6%

92 A photoactivation of 6-TG, ciprofloxacin and ofloxacin was associated with the generation of singlet

93 splaying an IC50 value of 18 microM, whereas ofloxacin was the least potent compound, with an IC50 va

94 he MICs for ciprofloxacin, levofloxacin, and ofloxacin were >32 mug/ml for all isolates.

95 M. tuberculosis isolates to moxifloxacin and ofloxacin were determined by the agar proportion indirec

96 dixic acid, ciprofloxacin, levofloxacin, and ofloxacin were determined for 100 clinical isolates of n

97 showed increased tolerance to ampicillin and ofloxacin, while a strain with glpD deleted had a decrea

98 Combining topical gatifloxacin or ofloxacin with intracameral agent was not more effective

99 rmed the cross-reactivity of levofloxacin or ofloxacin with these opiate screening assays.